JP2016515628A - 癌を治療するための複合薬 - Google Patents

癌を治療するための複合薬 Download PDF

Info

Publication number
JP2016515628A
JP2016515628A JP2016506653A JP2016506653A JP2016515628A JP 2016515628 A JP2016515628 A JP 2016515628A JP 2016506653 A JP2016506653 A JP 2016506653A JP 2016506653 A JP2016506653 A JP 2016506653A JP 2016515628 A JP2016515628 A JP 2016515628A
Authority
JP
Japan
Prior art keywords
compound
administered
less
dose
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016506653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515628A5 (OSRAM
Inventor
クリストファー ジェイ． スウィーニー，
クリストファー ジェイ． スウィーニー，
フィリッピ ダブリュー． カントフ，
フィリッピ ダブリュー． カントフ，
Original Assignee
エグゼリクシス， インコーポレイテッド
エグゼリクシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エグゼリクシス， インコーポレイテッド, エグゼリクシス， インコーポレイテッド filed Critical エグゼリクシス， インコーポレイテッド
Publication of JP2016515628A publication Critical patent/JP2016515628A/ja
Publication of JP2016515628A5 publication Critical patent/JP2016515628A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016506653A 2013-04-04 2014-04-04 癌を治療するための複合薬 Pending JP2016515628A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808516P 2013-04-04 2013-04-04
US61/808,516 2013-04-04
PCT/US2014/033008 WO2014165779A1 (en) 2013-04-04 2014-04-04 Drug combinations to treat cancer

Publications (2)

Publication Number Publication Date
JP2016515628A true JP2016515628A (ja) 2016-05-30
JP2016515628A5 JP2016515628A5 (OSRAM) 2017-05-25

Family

ID=50732309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016506653A Pending JP2016515628A (ja) 2013-04-04 2014-04-04 癌を治療するための複合薬

Country Status (11)

Country Link
US (1) US20160082019A1 (OSRAM)
EP (1) EP2983639A1 (OSRAM)
JP (1) JP2016515628A (OSRAM)
KR (1) KR20150138268A (OSRAM)
CN (1) CN108472242A (OSRAM)
AU (1) AU2014248001A1 (OSRAM)
BR (1) BR112015025408A8 (OSRAM)
CA (1) CA2908815A1 (OSRAM)
HK (1) HK1221424A1 (OSRAM)
MX (1) MX2015014046A (OSRAM)
WO (1) WO2014165779A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020059744A1 (ja) * 2018-09-18 2020-03-26 大鵬薬品工業株式会社 アシルチオウレア化合物とアビラテロンの併用療法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2758030C (en) 2009-01-16 2019-01-08 Exelixis, Inc. Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2621481B2 (en) 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
CA2826751C (en) 2011-02-10 2021-05-18 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
BR112015023109A2 (pt) 2013-03-15 2018-05-15 Exelixis Inc Metabolitos de n-(4-{[6,7-bis(metiloxi)quinoloin-4-il] oxi}fenil)-n -(4-fluorofenil)ciclopropano-1, 1- dicarboxamida
WO2014165786A1 (en) 2013-04-04 2014-10-09 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
CA2939546C (en) 2014-02-14 2023-01-17 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EA201691850A1 (ru) 2014-03-17 2016-12-30 Экселиксис, Инк. Дозирование составов, содержащих кабозантиниб
MA40386A (fr) 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
BR112017002318A2 (pt) 2014-08-05 2018-07-17 Exelixis, Inc. combinações de fármacos para tratar mieloma múltiplo.
CN109069499A (zh) 2016-04-15 2018-12-21 埃克塞里艾克西斯公司 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
CN117205313A (zh) * 2017-01-20 2023-12-12 埃克塞里艾克西斯公司 治疗癌症的卡博替尼与阿特珠单抗组合
EP3740210A4 (en) * 2018-01-19 2022-02-16 Indiana University Research and Technology Corporation THERAPEUTIC TARGETING OF ANDROGEN RECEPTOR PHOSPHORYLATION INDUCED BY A TYROSINE KINASE RECEPTOR INHIBITOR IN CANCER
CA3088200A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
TWI770624B (zh) 2018-06-15 2022-07-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501575A (ja) * 2006-08-25 2010-01-21 クオウガル バイオテクノロジー，インコーポレイテッド 癌を治療するための方法及び組成物
JP2012515220A (ja) * 2009-01-16 2012-07-05 エクセリクシス， インク． Ｎ−（４−｛［６，７−ビス（メチルオキシ）キノリン−４−イル］オキシ｝フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドのリンゴ酸塩およびその結晶質形態
JP2013501731A (ja) * 2009-08-07 2013-01-17 エグゼリクシス， インコーポレイテッド ｃ−Ｍｅｔモジュレーターの使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651730T3 (es) 2003-09-26 2018-01-29 Exelixis, Inc. Moduladores c-Met y métodos de uso
EP1773826A4 (en) * 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
WO2011009095A1 (en) * 2009-07-17 2011-01-20 Exelixis, Inc. Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
EP2621481B2 (en) * 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
CN103664778B (zh) * 2013-11-27 2017-04-05 苏州摩尔医药有限公司 一种抗肿瘤治疗药物卡博替尼的合成方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501575A (ja) * 2006-08-25 2010-01-21 クオウガル バイオテクノロジー，インコーポレイテッド 癌を治療するための方法及び組成物
JP2012082215A (ja) * 2006-08-25 2012-04-26 Cougar Biotechnology Inc 癌を治療するための方法及び組成物
JP2012515220A (ja) * 2009-01-16 2012-07-05 エクセリクシス， インク． Ｎ−（４−｛［６，７−ビス（メチルオキシ）キノリン−４−イル］オキシ｝フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドのリンゴ酸塩およびその結晶質形態
JP2013501731A (ja) * 2009-08-07 2013-01-17 エグゼリクシス， インコーポレイテッド ｃ−Ｍｅｔモジュレーターの使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EXELIXIS PRESS RELEASE, 2012.03.05, [平成30年1月26日検索], インターネット <HTTP://IR.EXELIXIS.COM/PH, JPN6018003391, ISSN: 0003906181 *
FRONTIERS IN ENDOCRINOLOGY, 2012.05.31, VOL. 3, ARTICLE 73, P. 1-11, JPN6018003392, ISSN: 0003906182 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020059744A1 (ja) * 2018-09-18 2020-03-26 大鵬薬品工業株式会社 アシルチオウレア化合物とアビラテロンの併用療法
JPWO2020059744A1 (ja) * 2018-09-18 2021-08-30 大鵬薬品工業株式会社 アシルチオウレア化合物とアビラテロンの併用療法
JP7540946B2 (ja) 2018-09-18 2024-08-27 大鵬薬品工業株式会社 アシルチオウレア化合物とアビラテロンの併用療法
AU2019342447B2 (en) * 2018-09-18 2025-05-29 Taiho Pharmaceutical Co., Ltd. Combination therapy of acylthiourea compound and abiraterone

Also Published As

Publication number Publication date
WO2014165779A1 (en) 2014-10-09
EP2983639A1 (en) 2016-02-17
CA2908815A1 (en) 2014-10-09
HK1221424A1 (zh) 2017-06-02
US20160082019A1 (en) 2016-03-24
CN108472242A (zh) 2018-08-31
KR20150138268A (ko) 2015-12-09
MX2015014046A (es) 2016-05-16
AU2014248001A1 (en) 2015-11-19
BR112015025408A8 (pt) 2018-07-10
BR112015025408A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
JP2016515628A (ja) 癌を治療するための複合薬
ES3031468T3 (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
KR20140094597A (ko) 암 치료를 정량하는 방법
KR20250056270A (ko) 활성화 fgfr3 유전자 변화를 갖는 고형 종양을 치료하는 방법
KR20200014903A (ko) 암을 치료하기 위한 액체 투여형
CN113365623A (zh) 用于治疗转移性去势敏感性前列腺癌的抗雄激素
Soriano-García et al. Pharmacological and safety evaluation of CIGB-300, a casein kinase 2 inhibitor peptide, administered intralesionally to patients with cervical cancer stage IB2/II
US20250090507A1 (en) Methods of Treating Cancer With a B-RAF Inhibitor
US20240058339A1 (en) Combination therapy for cancers with kras mutation
WO2023212071A1 (en) Combination and the use thereof
US11471457B2 (en) Method of treating epithelial growth factor receptor (EGFR) T790M-positive non-small cell lung cancer by administering a combination of a VEGFR-2 antibody and osimertinib
Huang et al. Hepatectomy combined with targeted and immunotherapy for CNLC stage IIIb hepatocellular carcinoma: a single-arm clinical trials protocol
WO2025104045A1 (en) Alectinib for the treatment of alk fusion-positive solid or cns tumours
US20250221970A1 (en) Combinations of a B-RAF Inhibitor and an Anti-EGFR Antibody for the Treatment of Cancer
US20250387523A1 (en) Combination therapy of radionuclide complex
Lin et al. Transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis
WO2023136837A1 (en) Use of tivozanib and durvalumab for treating hepatocellular carcinoma (hcc)
WO2021068867A1 (en) Combination therapy for cancers with kras mutation
CA3234495A1 (en) Combination therapy of radionuclide complex
WO2025117506A1 (en) Therapies for the treatment of inflammatory bowel disease
Pirisino et al. 18F-Fluciclovine
JP2025533900A (ja) エストロゲン受容体媒介性障害を治療する方法
HK40016051A (en) Combinations of cabozantinib and atezolizumab to treat cancer
Kong et al. Tislelizumab Plus Lenvatinib as the First-Line Therapy in Patients with Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Single-Arm, Single-Centre, Phase 2 Trial and Metabolic Biomarker Analysis
Schaefer et al. Positron Emission Tomography: Principles and Clinical Applications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170403

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180629

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181026